Owner/operator of an integrative pharmacy for 10+ years. Deep collaboration with a variety of medical, naturopathic physicians and clinics. Developed and dispensed innovative drug therapies including bioidentical hormones, autoimmune therapies, and topical treatments for chronic pain.
Co-founder and treating physician at the Bill Nelems Pain and Research Centre, the biggest comprehensive pain clinic in Canada with 20K+ patient visits a year. Clinical Assistant Professor at UBC. Triple certified in GP anesthesia, ER medicine and Pain Medicine.
After graduating from the University of Edinburgh BSc, Fraser emigrated to Canada and began scaling digital education and e-commerce platforms globally. He then became the Program Lead at one of the top tech incubators in Canada, Accelerate Okanagan (AO).
During his time at AO he helped hundreds of businesses scale through innovative program design, strategic planning and detailed operational reviews. A pioneer in the biotech industry, Fraser was inspired by his own personal healing journey to amass the worlds’ largest catalogue of psilocybin mushroom strains to bring these powerful natural medicines to the world. His vision to inspire healthy and cooperative communities is behind everything EntheoTech does.
Serial entrepreneur with extensive experience in business development, strategic planning and finance. Cannabis consultant with a 20-year background in cultivation, facility set up and operations. Director in a clean tech start up that recently sold.
PhD candidate in Neuroscience from McGill University. Lead/co-author on over a dozen scientific publications and book chapters on topics including psychedelics and the default mode network. Currently conducting research on the brain mechanisms underlying psychedelics, in collaboration with Dr. Robin Carhart-Harris from the Imperial College London Center for Psychedelic Research.
Supporting non-profit foundations with initiatives to help our community access our programs.
Psychedelic-assisted Therapies in a unique integrative model to ensure long lasting, beneficial results.
Our goal is to help patients physically with innovative pain treatments and emotionally/mentally with Therapeutic Experiences to create a truly disease-modifying approach and long term positive outcomes.
Our Odyssey Therapeutic Experiences using psychoactive substances such as psilocybin, ketamine, MDMA and other entheogens, along with Integrative Pain Management treatments are designed promote mental health and global wellness.
When breaking ground in a new industry, data is crucial. Over the last year, we have been collecting data and testimonies from clients who have come through our doors for treatment.
One of the scores we have had the most profound feedback on is the PHQ9. PHQ9 is one of the main measures of depression and is a scale that runs from 0 to 27 (27 being severe depression). The PHQ-9 can function as a screening tool, an aid in diagnosis, and a symptom-tracking tool that can help track a patient’s overall depression severity as well as the improvement of specific symptoms with treatment. The data in the chart shows the robust impact of our innovative and holistic Odyssey treatment.
The graph indicates the majority of Odyssey patients exhibited a significant drop in PHQ9 at approximately 3 months post-treatment. Given that most patients relapse following a ketamine treatment within 2-4 weeks, this data suggests that our Odyssey Ketamine-assisted Therapy framework can significantly extend symptom reductions for some patients. Effects were largest in patients with medium severity at baseline (PHQ9 = ~12-18).
